GSK’s (GSK) “Hold” Rating Reiterated at Deutsche Bank

Deutsche Bank reiterated their hold rating on shares of GSK (LON:GSK) in a report published on Tuesday morning,Digital Look reports. They currently have a GBX 2,000 price target on the stock.

Several other research firms have also recently weighed in on GSK. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 price target on shares of GSK in a report on Tuesday, October 20th. Berenberg Bank reiterated a “buy” rating and set a GBX 2,200 price objective on shares of GSK in a research note on Tuesday, November 3rd. Finally, Royal Bank Of Canada began coverage on shares of GSK in a research note on Tuesday, September 8th. They set a “sector perform” rating and a GBX 1,975 price objective for the company. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of GBX 2,145.

GSK Price Performance

Shares of LON:GSK opened at GBX 1,901 on Tuesday. The firm has a market capitalization of £76.21 billion, a price-to-earnings ratio of 17.78, a PEG ratio of 1.24 and a beta of 0.28. GSK has a one year low of GBX 1,690 and a one year high of GBX 2,282. The company’s fifty day moving average price is GBX 1,845.62 and its 200-day moving average price is GBX 1,951.49. The company has a debt-to-equity ratio of 126.38, a current ratio of 0.86 and a quick ratio of 0.73.

GSK (LON:GSK) last issued its quarterly earnings data on Wednesday, October 28th. The company reported GBX 54.60 earnings per share for the quarter. GSK had a return on equity of 24.64% and a net margin of 12.97%. The firm had revenue of GBX 888.70 billion for the quarter. On average, equities research analysts anticipate that GSK will post 175.98 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Jonathan Symonds bought 1,500 shares of the stock in a transaction on Friday, September 18th. The shares were bought at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal bought 637 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were acquired at an average cost of GBX 4,985 per share, with a total value of £31,754.45. Insiders bought a total of 2,151 shares of company stock worth $6,021,921 over the last ninety days. Corporate insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.